Kezar Life Sciences (NASDAQ:KZR – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Earnings & Valuation
This table compares Kezar Life Sciences and Bicycle Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kezar Life Sciences | N/A | N/A | -$56.03 million | ($6.17) | -1.18 |
| Bicycle Therapeutics | $72.86 million | 4.26 | -$218.96 million | ($3.15) | -1.41 |
Profitability
This table compares Kezar Life Sciences and Bicycle Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kezar Life Sciences | N/A | -55.42% | -47.87% |
| Bicycle Therapeutics | -344.95% | -35.74% | -29.54% |
Volatility and Risk
Kezar Life Sciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Kezar Life Sciences and Bicycle Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kezar Life Sciences | 2 | 4 | 0 | 0 | 1.67 |
| Bicycle Therapeutics | 1 | 3 | 5 | 0 | 2.44 |
Kezar Life Sciences currently has a consensus target price of $6.00, indicating a potential downside of 17.70%. Bicycle Therapeutics has a consensus target price of $14.00, indicating a potential upside of 214.61%. Given Bicycle Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Kezar Life Sciences.
Institutional and Insider Ownership
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Bicycle Therapeutics beats Kezar Life Sciences on 10 of the 13 factors compared between the two stocks.
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
